(S (S (VP (VBG Predicting) (NP (NP (NN response)) (PP (TO to) (NP (JJ neoadjuvant) (NN therapy)))))) (VP (VBZ is) (NP (DT a) (VBG vexing) (NN challenge)) (PP (IN in) (NP (NN breast) (NN cancer)))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP evaluate) (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (JJ deep) (NN learning))) (S (VP (TO to) (VP (VB predict) (NP (NP (NN response)) (PP (TO to) (NP (NP (JJ HER2-targeted) (JJ neo-adjuvant) (NN chemotherapy)) (PRN (-LRB- -LRB-) (NP (NNP NAC)) (-RRB- -RRB-))))) (PP (IN from) (NP (NP (JJ pre-treatment) (JJ dynamic) (JJ contrast-enhanced) (PRN (-LRB- -LRB-) (NNP DCE) (-RRB- -RRB-)) (NNP MRI)) (VP (VBD acquired) (ADVP (RB prior) (PP (TO to) (NP (NN treatment)))))))))))) (. .))
(S (PP (IN In) (NP (NP (DT a) (JJ retrospective) (NN study)) (VP (VBG encompassing) (NP (NP (NNP DCE-MRI) (NNS data)) (PP (IN from) (NP (NP (DT a) (NN total)) (PP (IN of) (NP (CD 157) (NNP HER2+) (NN breast) (NN cancer) (NNS patients))) (PP (IN from) (NP (CD 5) (NNS institutions))))))))) (, ,) (NP (PRP we)) (VP (VBD developed) (CC and) (VBD validated) (NP (NP (DT a) (JJ deep) (NN learning) (NN approach)) (PP (IN for) (S (VP (VBG predicting) (NP (NP (NP (JJ pathological) (JJ complete) (NN response)) (PRN (-LRB- -LRB-) (NP (NN pCR)) (-RRB- -RRB-))) (PP (TO to) (NP (JJ HER2-targeted) (NNP NAC)))) (ADVP (RB prior) (PP (TO to) (NP (NN treatment))))))))) (. .))
(S (NP (NP (CD 100) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD received) (NP (NNP HER2-targeted) (JJ neoadjuvant) (NN chemotherapy)) (PP (IN at) (NP (DT a) (JJ single) (NN institution))))))) (VP (VBD were) (VP (VBN used) (S (VP (TO to) (VP (VP (VB train) (PRN (-LRB- -LRB-) (NP (NN n=85)) (-RRB- -RRB-))) (CC and) (VP (NN tune) (PRN (-LRB- -LRB-) (ADJP (JJ n=15)) (-RRB- -RRB-))) (NP (NP (DT a) (JJ convolutional) (JJ neural) (NN network)) (PRN (-LRB- -LRB-) (NP (NNP CNN)) (-RRB- -RRB-))) (S (VP (TO to) (VP (VB predict) (NP (NN pCR)))))))))) (. .))
(S (NP (NP (DT A) (JJ multi-input) (NNP CNN)) (VP (VBG leveraging) (NP (UCP (DT both) (JJ pre-contrast) (CC and) (JJ late) (JJ post-contrast)) (JJ DCE-MRI) (NNS acquisitions)))) (VP (VBD was) (VP (VBN identified) (S (VP (TO to) (VP (VB achieve) (NP (JJ optimal) (NN response) (NN prediction)) (PP (IN within) (NP (NP (DT the) (NN validation) (NN set)) (PRN (-LRB- -LRB-) (NP (NNP AUC=0.93)) (-RRB- -RRB-))))))))) (. .))
(S (NP (DT This) (NN model)) (VP (VBD was) (ADVP (RB then)) (VP (VBN tested) (PP (IN on) (NP (NP (CD two) (JJ independent) (VBG testing) (NNS cohorts)) (PP (IN with) (NP (JJ pre-treatment) (NNP DCE-MRI) (NN data))))))) (. .))
(S (NP (PRP It)) (VP (VBD achieved) (NP (JJ strong) (NN performance)) (PP (IN in) (NP (NP (NP (DT a) (ADJP (CD 28) (JJ patient)) (VBG testing) (NN set)) (PP (IN from) (NP (DT a) (JJ second) (NN institution))) (PRN (-LRB- -LRB-) (NP (NP (NNP AUC=0.85)) (, ,) (NP (ADJP (CD 95) (NN %)) (NNP CI) (CD 0.67-1.0)) (, ,) (NP (NN p=.0008))) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (ADJP (CD 29) (NN patient)) (NN multicenter) (NN trial)) (PP (VBG including) (NP (NP (NNS data)) (PP (IN from) (NP (NP (CD 3) (JJ additional) (NNS institutions)) (PRN (-LRB- -LRB-) (NP (NNP AUC=0.77)) (, ,) (NP (ADJP (CD 95) (NN %)) (NNP CI) (CD 0.58-0.97)) (, ,) (NP (NN p=0.006)) (-RRB- -RRB-)))))))))) (. .))
(S (NP (JJ Deep) (JJ learning-based) (NN response) (NN prediction) (NN model)) (VP (VBD was) (VP (VBN found) (S (VP (TO to) (VP (VB exceed) (NP (NP (NP (DT a) (JJ multivariable) (NN model)) (VP (VBG incorporating) (NP (NP (JJ predictive) (JJ clinical) (NNS variables)) (PRN (-LRB- -LRB-) (NP (NP (NNP AUC)) (NNP <) (NNP .65) (PP (IN in) (NP (VBG testing) (NNS cohorts)))) (-RRB- -RRB-))))) (CC and) (NP (NP (DT a) (NN model)) (PP (IN of) (NP (NP (JJ semi-quantitative) (NNP DCE-MRI) (NN pharmacokinetic) (NNS measurements)) (PRN (-LRB- -LRB-) (NP (NP (NP (NNP AUC)) (NNP <) (NNP .60)) (PP (IN in) (NP (VBG testing) (NNS cohorts)))) (-RRB- -RRB-))))))))))) (. .))
(S (NP (NP (DT The) (NNS results)) (VP (VBN presented) (PP (IN in) (NP (DT this) (NN work))) (PP (IN across) (NP (JJ multiple) (NNS sites))))) (VP (VBP suggest) (SBAR (IN that) (S (PP (IN with) (NP (JJ further) (NN validation))) (NP (JJ deep) (NN learning)) (VP (MD could) (VP (VB provide) (NP (NP (DT an) (JJ effective) (CC and) (JJ reliable) (NN tool)) (SBAR (S (VP (TO to) (VP (VB guide) (NP (JJ targeted) (NN therapy)) (PP (IN in) (NP (NN breast) (NN cancer))) (, ,) (S (ADVP (RB thus)) (VP (VBG reducing) (NP (NP (NN overtreatment)) (PP (IN among) (NP (NNP HER2+) (NNS patients)))))))))))))))) (. .))
